Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chinook Therapeutics Inc KDNY

Healthcare Biotechnology
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase... see more

Recent & Breaking News (NDAQ:KDNY)

Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting

GlobeNewswire October 9, 2017

Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology

GlobeNewswire September 27, 2017

Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas

GlobeNewswire September 26, 2017

Aduro Biotech to Present at Three Investor Conferences in the Second Half of September

GlobeNewswire September 18, 2017

Aduro Biotech to Present at Three Investor Conferences in the First Half of September

GlobeNewswire August 31, 2017

Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents

GlobeNewswire August 9, 2017

Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference

GlobeNewswire August 3, 2017

Aduro Biotech Reports Second Quarter 2017 Financial Results

GlobeNewswire August 2, 2017

Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017

GlobeNewswire July 27, 2017

Today's Research Report Coverage on Biotech Stocks -- ACADIA Pharma, Aduro BioTech, Agios Pharma, and AveXis

PR Newswire July 20, 2017

Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer

GlobeNewswire July 13, 2017

Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma

GlobeNewswire June 29, 2017

Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma

GlobeNewswire June 28, 2017

Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas

GlobeNewswire June 1, 2017

Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting

GlobeNewswire May 26, 2017

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma

GlobeNewswire May 17, 2017

Aduro Biotech Reports First Quarter 2017 Financial Results

GlobeNewswire May 2, 2017

Aduro Biotech to Present at Two Investor Conferences in May

GlobeNewswire April 25, 2017

Aduro Biotech Announces Management Promotions

GlobeNewswire April 20, 2017

Aduro Biotech, Inc. (Nasdaq: ADRO) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire March 27, 2017